Диссертация (1140088), страница 19
Текст из файла (страница 19)
Олисова О.Ю. Современные подходы к ведению больных псориазом//Русский медицинский журнал,- 2004,-№4.- с 182-185.;13. Олисова О.Ю. Циклоспорин А в дерматологической практике// Фарматека.- 2008. - 19(173). - с.74-78.14. Олисова О.Ю. Псориаз: эпидемиология, патогенез, лечение. // Consiliummedicum. –2010- №5.-с.34-37.15. Олисова О.Ю., Смирнов К.В., Пинсон И.Я. Фототерапия псориаза//Российский журнал кожных и венерических болезней. - 2006. - №3.-с.38-4216.Опарин Р.Б. Оптимизация терапии псориаза у детей по клиникоиммунологическим показателям. Автореферат дисс. на соиск. уч.ст. к.м.н.,Москва, 1998.-с. 29.17.
Пирузян Е.В., Тогоева Л.Т., Аветикян С.С. и др. Этапы наружной терапииразных форм псориаза// Клиническая дерматология и венерология- 2007 -.№2,- с.71-74.18. Скрипкин Ю.К. Псориаз: лечение и профилактика рецидивов//.Терапевтический архив,- 1993 - №10 – с.67-71.19. Скрипкин Ю.К., Богуш П.Г., Круглова Л.С. и др.Новые возможностинаружной терапии псориаз // Вестник дерматологии и венерологии.- 2006 №3,- с.33-37.20. Скрипкин Ю.К. , Мордовцев В.Н. Кожные и венерические болезни.
//Москва, Медицина- 1999г.-с.140.11121.СмирноваИ.О.,КветнойНейроиммуноэндокринология кожи иИ.М.,КнязышнИ.В.,молекулярные маркеры ее старения.СПб.,- 2005.-с.288.22.Филимонкова Н.Н. Псориатическая болезнь: клиникоиммунологическиеварианты, патогенетическое обоснование дифференцированной терапии//автореф. дисс. док.мед. наук. — Челябинск. 2001.-с. 44.23.Фицпатрик Т., Джонсон Р., Вулф К и др, Дерматология.- Москва,- 1999.с.1248.24. Abou EL-Ela M, Nagui N, Mahgoub D, et al.
Expression of cyclin D1 and p16in psoriasis before and after phototherapy.// Clin Exp Dermatol.- 2010 -№35-р781–785.25. Acosta-Rodriguez EV, Napolitani G. Lanzavecchia .et al. Inteleukin 1beta and 6but not transforming growth factor-beta are essential for the differentiation ofinterleukin 17-producing human T helper cells.// Nat.Immunol.- 2007.- №8.-р 942948.26. Afshar M, Martinez AD, Gallo RL,еt al. Induction and exacerbation of psoriasiswith Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases.// JEur Acad Dermatol Venereol.- 2013.-v 27(6).- р 771-77827. Albanesi CC, Scarponi S, Pallotta R et al.
Chemerin expression marks earlypsoriasisskin lesionsandcorrelateswith plasmacytoiddendriticcellrecruitment//J.Exp.Med-. 2009.-№ 206.р 249-258.28.Altmann E.M. Kim T., Kripke M., Immunosuppression by factors released fromUV-irradiated epidermal cells: selective effects on the generation of contact anddelayed hypersensitivity after exposure to UVA and UVB radiation// Invest.DermatoL-1990.-v.94.-р.26-32.29. Antiga E, Volpi W, Chiarini C, еt al.The role of etanercept on the expression ofmarkers of T helper 17 cells and their precursors in skin lesions of patients withpsoriasis vulgaris.// Int J Immunopathol Pharmacol- 2010.- v 23(3)- р767-774.11230. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies.//J Am Heart Assoc -2013-v 2(2).-е000062.31.
Asadullah K, Sterry W, Stephanek K, et al. IL-10 is a key cytokine in psoriasis.Proof of principle by IL-10 therapy: a new therapeutic approach.// J Clin Invest.1998.-№101- р783–794.32. Austin LM, Ozawa M, Kikuchi T et al. The majority of the epidermal T cells inpsoriasis vulgaris lesions can produce type I cytokines, interferon-γ, interleukin-2,and tumor necrosis factor-α, defining TC1 (1cytotoxic T lymphocyte) and TH1effector populations: a type 1 differentiation bias is also measured in circulatingblood T cells in psoriatic patients.// J.Invest.Dermatol.- 1999.-№ 113-р 752-75933.Azizi G, Yazdani R, Mirshafiey A.
Th22 cells in autoimmunity: a review ofcurrent knowledge. //Eur Ann Allergy Clin Immunol.- 2015.-v 47(4)-р108-117.34. Baker BS, Ovigne JM, Powles AV et al. Normal keratinocytes express Toll-likereceptors (TLRs) 1, 2, 5: modulation of TLR expression in chronic plaquepsoriasis.// Br.J.Dermatol.- 2003.- v. 148(4).- р. 670-679.35. Barr RM, Walker SL, Tsang W, et al. Suppressed alloantigen presentation,increased TNF-alpha, IL-1, IL-1Ra, IL-10, and modulation of TNF-R in UVirradiated human skin.// J Invest Dermatol.-1999.-v.112(5).-р.692-698.36.
Bennett SR, Carbone FR, Karamalis F еt al.Help for cytotoxic-T-cell responsesis mediated by CD40 signalling.// Nature-. 1998- v.393(6684)-р478-480.37. Bianchi M.E. DAMPs, PAMРs and alarmins: all we need to know about danger.//J.Leukoc.Biol.- 2007.-№ 81.-р 1-5.38.
Black AP, Ardern-Jones MR, Kasprowicz V et al. Human keratinocyte inductionof rapid effector function in antigen-specific memory CD4+ and CD8+T cells.//Eur.J.Immunol.- 2007.-№ 37-р 1485-149339. Blumberg H, Conklin D, Xu WF et al. Interleukin 20: discovery, receptoridentification, and role in epidermal function.// Cell.- 2001.-№ 104.-р 9-19.40. Boehncke WH, Boehncke S, Schon MP. Managing comorbid disease in patientswith psoriasis.// BMJ- 2010-340.-b5666.11341.Boehncke WH, Boehncke S, Tobin AM еt al. The ‘psoriatic march’: A concept ofhow severe psoriasis may drive cardiovascular comorbidity.// Exp Dermatol -2011.№20-р303- 307.42..
Boehncke S, Thaci D, Beschmann H et al Psoriasis patients show signs of insulinresistance.// Br J Dermatol.- 2007.-№157.-р.1249-1251.43. Boniface K, Bernard EX, Garcia M et al. IL-22 inhibits epidermal differentiationand induces proinflammatary gene expression and migration of humankeratinocytes.// J.Immunol.- 2005.-№174.-р. 3695-3702.44. Boniface K, Cuignouard E, Pedrretti Net al. A role for T cell-derivedinterleukin 22 in psoriasis skin inflammation.// Clin.Exp.Immunol.
-2007.-№ 150.р.407-415.45. Bonis В., Kemeny L., Dobozy A. et al. 308 eximer laser for psoriasis// Lancet.1997.-v. 350.-p.1522.46. Bos J. D. and De Rie M. A. The pathogenesis of psoriasis: immunological factsand speculations.//Immunol Today.- 1999 - v.20- №l .- P.40-46.47.
Bronsard V, Paul C, Prey S et al. What are the best outcome measures forassessing quality of life in plaque type psoriasis systematic review of the literature.//J Eur Acad Dermatol Venereol.-2010- №24( Suppl 2)-р.17–22.48. Burden A.D. Javed S., Bailey M.
et al. Genetics of psoriasis. //J Invest Dermatol.– 1999 – v.112 - №4 - P: 514 - 516.49. Cesare A, Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesisof psoriasis.// J.Invest.Dermatol.- 2009.-№ 129.-р. 1339-1350.50. Chamorro CI, Weber G, Grönberg A еt al.The human antimicrobial peptide LL37 suppresses apoptosis in keratinocytes. //J Invest Dermatol.- 2009.- v.129(4)р.937-944.51. Christophers E Psoriasis–epidemiology and clinical spectrum.
//Clin ExpDermatol.- 2001.-v.26(4)-р.314-320.52. Conrad C, Boyman O, Tonel G et al. Alpha1beta1 integrin in crucial foraccumulation of epidermal T cells and the development of psoriasis.// Nat.Med.2007.-№ 13.-р. 836-842.11453. Cosmi L, De Palma R, Santarlasci V et al. Human interleukin 17-producing cellsoriginate from a CD161+CD4+ T cell precursor.// J.Exp.Med.- 2008,-v. 205(8).-р.1903-1916.54.
Dombrowski Y, Perik M, Koglin S et al. Cytosolic DNA triggers inflammasomeactivation in keratinocytes in psoriatic lesions.// Sci.Transl.Med.- 2011.-№ 3.-р.1-9.55. Dorschner RA, PestniamaspVK, Tamakuwata S et al. Cutaneous injurу inducesthe release of cathelicidin antimicrobial peptides active against group ASteptococcus.// J.Invest.Dermatol.- 2001.-v. 117(1).-р. 91-97.56. Duffy D. L., Spelman L. S. and Martin N.
G. Psoriasis in Australian twins.// JAm Acad Dermatol.- 1993 - v.29 - №3.- p.428-434.57. DuhenT, Geiger R, Jarrossay D et al. Production of interleukin 22 but notinterleukin 17 by a subset of a human skin-homing memory T cells.// Nat.Immunol.2009.-№ 10.р. 857-863.58. Durham LE, Kirkham BW, Taams LS. Contribution of the IL-17 Pathway toPsoriasis and Psoriatic Arthritis.// Curr Rheumatol Rep.- 2015.-v. 17(8)-р.529.59. Enk CD, Sredni D, Blauvelt A еt al. Induction of IL-10 gene expression in humankeratinocytes by UVB exposure in vivo and in vitro.// J Immunol.
-1995.-№154.р.4851–4856.60. Farber E. M., Nail M. L. Watson W. Natural history of psoriasis in 61 twinpairs.//Arch Dermatol.- 1974 - v. 109- №2.- р.207-211.61 Feldmeyer L, Keller M, Niklaus G et al. The inflammasome mediates UVBinduced activation and secretion of interleukin-1β by keratinocytes.// Curr Biol2007.-v.17(13). –р.1140-1145.62. Fernandes-Alnemri T, Yu JW, Datta P et al. AIM2 activates the inflammasomeand cell death in response to cytoplasmic DNA.// Nature.- 2009.-№ 458.-р. 509-513.63. Fits L, Mourits S, Voerman JS еt al.Imiquimod-induced psoriasis-like skininflammation in mice is mediated via the IL-23/IL-17 axis.// J Immunol.
-2009.v.182(9).-р. 5836-5845.11564. Frohm M, Agerberth B, Ahangari G еt al.The expression of the gene coding forthe antibacterial peptide LL-37 is induced in human keratinocytes duringinflammatory disorders.// J Biol Chem.- 1997. –v.272(24).-р.15258-1526365 Gallo RL, Ono M, Povsic T at al.Syndecans, cell surface heparan sulfateproteoglycans, are induced by a proline-rich antimicrobial peptide from wounds.//Proc Natl Acad Sci U S A.- 1994.-v. 91(23).-р.11035-11039.66. Ganguly D, Chamilos G, Lande R еt al.Self-RNA-antimicrobial peptidecomplexes activate human dendritic cells through TLR7 and TLR8.// J Exp Med.2009.-v. 31;206(9).-р.1983-199467.
Gisondi P, Cazzaniga S, Chimenti S et al. Metabolic abnormalities associatedwith initiation of systemic treatment for psoriasis: evidence from the Italian PsocareRegistry.// J Eur Acad Dermatol Venereol.- 2013,-№ 27.-р.30–41.68. Goodman WA, Levine AD, MAssari JV et al. IL-6 signaling in psoriass preventsimmune suppression by regulatory T cells.// J.Immunol.- 2009.-№ 183.-р.
31703176.69. Gregorio J, Meller S, Conrad C et al.Plasmacytoid dendritic cells sense skininjury and promote wound healing through type I interferons.// J Exp Med.- 2010. –v.207(13).-р.2921-2930.70. Grine L, Dejager L, Libert C, Vandenbroucke RE. An inflammatory triangle inpsoriasis: TNF, type I IFNs and IL-17.// Cytokine Growth Factor Rev.- 2015.v.26(1).-р.25-33.71.Gudjonsson JE1, Ding J, Johnston A et al.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
